COX-2 inhibitors in oncology
- 31 August 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30, 2-8
- https://doi.org/10.1016/s0093-7754(03)00328-2
Abstract
No abstract availableFunding Information
- National Cancer Institute
This publication has 18 references indexed in Scilit:
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Potential utility of COX-2 inhibitors in chemoprevention and chemotherapyExpert Opinion on Investigational Drugs, 1999
- Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)Cell, 1996
- Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasiaDigestive Diseases and Sciences, 1996
- Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumorsGastroenterology, 1996
- Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health ProfessionalsAnnals of Internal Medicine, 1994
- Aspirin use, cancer, and polyps of the large bowelCancer, 1993
- Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme.BMJ, 1993
- Reduced Risk of Large-Bowel Adenomas Among Aspirin UsersJNCI Journal of the National Cancer Institute, 1993
- Aspirin Use and Reduced Risk of Fatal Colon CancerNew England Journal of Medicine, 1991